Analysts split on Biogen's potential sale

11/14/2007 | Boston Globe (tiered subscription model), The

A biotech analyst said the potential sale of Biogen Idec to a major drugmaker could reach up to $30 billion if buyers remain positive on the future of its multiple sclerosis drug Tysabri in the market. However, some stock analysts believe the company might not be able to find a buyer due to competition and Biogen's drug-development deals with Elan Corp. and Genentech.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Confidential
Washington, D.C., DC
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations